期刊
EXPERT OPINION ON PHARMACOTHERAPY
卷 12, 期 2, 页码 269-283出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656566.2011.533169
关键词
-
资金
- German Jose Carreras Leukemia Foundation [DJCLS H09/01f, H06/04v, H03/01]
- Deutsche Krebshilfe [106642]
- European Commission [LSHC-CT-2004-503216]
Areas covered: Definition of failure, its causes, the various approaches to the treatment of imatinib failure such as imatinib dose escalation, second-generation tyrosine kinase inhibitors and stem cell transplantation, and monitoring of residual disease are covered in this review. Selected investigational agents and the management of blast crisis are also reviewed. After reading the review the reader will understand how to manage imatinib failure. Expert opinion: Imatinib failure can be managed in most cases by a careful appraisal of its causes and a rational selection of treatment options.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据